Everolimus (RAD001) in Combination With Intravenous Carboplatin in Taxane- and Anthracycline-Pretreated Patients With Progressive Metastatic Breast Cancer.

Trial Profile

Everolimus (RAD001) in Combination With Intravenous Carboplatin in Taxane- and Anthracycline-Pretreated Patients With Progressive Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Carboplatin
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Nov 2014 Status changed from completed to discontinued, according to European Clinical Trials Database record.
    • 12 Jan 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 21 Apr 2012 Planned number of patients changed from 54 to 58 as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top